Trials Sponsors Conditions Drugs Pricing

Conditions

Pancreatic Cancer

Keywords

adenocarcinoma of the pancreasrecurrent pancreatic cancerstage IV pancreatic cancer

Interventions

7-hydroxystaurosporineDrug

fluorouracilDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed adenocarcinoma of the pancreas * Progressive disease after gemcitabine-based chemotherapy for metastatic disease * At least 1 unidimensionally measurable metastatic lesion * At least 20 mm by conventional techniques OR * At least 10 mm by spiral CT scan * Primary disease site is not considered a measurable lesion * No known brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-1 OR * Karnofsky 70-100% Life expectancy * More than 8 weeks Hematopoietic * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin normal * AST/ALT no greater than 2.5 times upper limit of normal Renal * Creatinine normal OR * Creatinine clearance at least 60 mL/min Cardiovascular * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac tachyarrhythmia Pulmonary * No symptomatic chronic obstructive pulmonary disease * No pulmonary embolism within the past 6 months Other * No prior allergic reactions to compounds of similar chemical or biological composition to UCN-01 or other agents used in this study * No diabetes mellitus uncontrolled by insulin or oral hypoglycemic agents * No uncontrolled concurrent illness * No ongoing or active infection * No psychiatric illness or social situation that would preclude study * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception before, during, and for 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunotherapy Chemotherapy * See Disease Characteristics * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * No more than 1 prior chemotherapy regimen for metastatic or recurrent disease * No prior fluorouracil in the adjuvant or inoperable, locally advanced setting (except as a radiosensitizer) * No other concurrent chemotherapy Endocrine therapy * Not specified Radiotherapy * More than 4 weeks since prior radiotherapy and recovered * No prior mediastinal irradiation * No concurrent radiotherapy Surgery * Not specified Other * No prior UCN-01 or other cyclin-dependent kinase inhibitors * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent investigational or commercial anticancer agents or therapies * No concurrent anticonvulsant medications

Sponsors & Collaborators

Memorial Sloan Kettering Cancer Center
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

7-hydroxystaurosporineFluorouracil

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

UracilPyrimidinonesPyrimidines

Study Officials

Gary K. Schwartz, MD
Memorial Sloan Kettering Cancer Center
STUDY CHAIR

Study Design

Study Type: interventional
Phase: phase 2
Masking: NONE
Purpose: TREATMENT
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 6, 2002

First Posted

January 27, 2003

Study Start

July 2002

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

September 2004

Actual (reported)

UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations